[{"id":"849f2903-a63e-4422-bd1f-c14fc38ea333","acronym":"BGB-290-102","url":"https://clinicaltrials.gov/study/NCT03333915","created_at":"2021-01-17T17:46:43.275Z","updated_at":"2025-02-25T16:52:02.784Z","phase":"Phase 1/2","brief_title":"Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03333915 - BGB-290-102","lead_sponsor":"BeiGene","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 128","initiation":"Initiation: 12/21/2016","start_date":" 12/21/2016","primary_txt":" Primary completion: 08/24/2020","primary_completion_date":" 08/24/2020","study_txt":" Completion: 08/11/2021","study_completion_date":" 08/11/2021","last_update_posted":"2025-02-04"},{"id":"20ec0814-6de7-4db9-a034-30ef491a8c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT05526924","created_at":"2022-09-02T17:00:19.091Z","updated_at":"2025-02-25T16:27:01.989Z","phase":"Phase 1","brief_title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","source_id_and_acronym":"NCT05526924","lead_sponsor":"University of Chicago","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-11-22"},{"id":"ca13f616-bab8-4eca-8a94-b55ce8f19f86","acronym":"PNOC017","url":"https://clinicaltrials.gov/study/NCT03749187","created_at":"2021-01-18T18:23:03.471Z","updated_at":"2024-07-02T16:35:02.572Z","phase":"Phase 1","brief_title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","source_id_and_acronym":"NCT03749187 - PNOC017","lead_sponsor":"University of California, San Francisco","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/30/2029","study_completion_date":" 07/30/2029","last_update_posted":"2024-05-20"},{"id":"7d35f15f-f2de-4fad-9cce-09c440f911d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652283","created_at":"2022-12-15T14:58:15.323Z","updated_at":"2024-07-02T16:35:05.706Z","phase":"Phase 2","brief_title":"Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","source_id_and_acronym":"NCT05652283","lead_sponsor":"Bai-Rong Xia","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib) • Sulanda (surufatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2022","start_date":" 11/06/2022","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-06"},{"id":"04495210-d346-4ec0-a195-5cf3933896b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038839","created_at":"2021-09-09T13:53:06.097Z","updated_at":"2024-07-02T16:35:09.419Z","phase":"Phase 1","brief_title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","source_id_and_acronym":"NCT05038839","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 06/03/2024","primary_completion_date":" 06/03/2024","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2024-04-16"},{"id":"68997bd5-1ca2-4ac4-86f7-940964b6a1c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914742","created_at":"2021-01-18T19:16:33.428Z","updated_at":"2024-07-02T16:35:20.037Z","phase":"Phase 1/2","brief_title":"BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations","source_id_and_acronym":"NCT03914742","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 01/03/2020","start_date":" 01/03/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-02-09"},{"id":"c930668b-00d5-4371-a74e-d16c53d65c4b","acronym":"BGB-290-103","url":"https://clinicaltrials.gov/study/NCT03150810","created_at":"2021-01-18T15:31:48.587Z","updated_at":"2024-07-02T16:35:47.128Z","phase":"Phase 1b","brief_title":"Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03150810 - BGB-290-103","lead_sponsor":"BeiGene","biomarkers":" AR • HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["AR • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 06/28/2017","start_date":" 06/28/2017","primary_txt":" Primary completion: 05/04/2023","primary_completion_date":" 05/04/2023","study_txt":" Completion: 05/04/2023","study_completion_date":" 05/04/2023","last_update_posted":"2023-05-25"},{"id":"6e3f90ef-b0d9-4781-a5ea-e47823f7ed76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603365","created_at":"2021-01-19T20:30:55.953Z","updated_at":"2024-07-02T16:35:47.797Z","phase":"Phase 2","brief_title":"Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer","source_id_and_acronym":"NCT04603365","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" FH","pipe":"","alterations":" ","tags":["FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 05/07/2023","primary_completion_date":" 05/07/2023","study_txt":" Completion: 05/07/2023","study_completion_date":" 05/07/2023","last_update_posted":"2023-05-17"},{"id":"354dc2c5-feeb-41d3-8c1c-e0fb0c8edd00","acronym":"IMPARP-HRD","url":"https://clinicaltrials.gov/study/NCT04985721","created_at":"2021-08-02T14:53:05.727Z","updated_at":"2024-07-02T16:35:53.270Z","phase":"Phase 2","brief_title":"A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects","source_id_and_acronym":"NCT04985721 - IMPARP-HRD","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD","tags":["BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-03-15"},{"id":"468ac124-7c65-4c19-a0fa-b750d5f397b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376722","created_at":"2022-05-17T12:54:18.320Z","updated_at":"2024-07-02T16:35:58.119Z","phase":"Phase 2","brief_title":"A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer","source_id_and_acronym":"NCT05376722","lead_sponsor":"Hongqian Guo","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/22/2022","start_date":" 02/22/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-01-05"},{"id":"37b1fa36-01cb-4b6e-a216-bd6d853594b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05669768","created_at":"2023-01-03T14:58:53.111Z","updated_at":"2024-07-02T16:35:58.336Z","phase":"Phase 2","brief_title":"Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy","source_id_and_acronym":"NCT05669768","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Partruvix (pamiparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-01-02"},{"id":"ca285fd3-5430-49c4-b992-a9c29d27f747","acronym":"BRIGHT","url":"https://clinicaltrials.gov/study/NCT05044871","created_at":"2021-09-16T15:55:21.337Z","updated_at":"2024-07-02T16:36:02.078Z","phase":"Phase 2","brief_title":"Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05044871 - BRIGHT","lead_sponsor":"Tongji Hospital","biomarkers":" BRCA1","pipe":"","alterations":" ","tags":["BRCA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Partruvix (pamiparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2022-10-20"},{"id":"66bbeb83-4f4a-45e8-bb51-d66065bfe136","acronym":"BGB-290-201","url":"https://clinicaltrials.gov/study/NCT03575065","created_at":"2021-01-18T17:35:26.467Z","updated_at":"2024-07-02T16:36:04.374Z","phase":"Phase 2","brief_title":"Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China","source_id_and_acronym":"NCT03575065 - BGB-290-201","lead_sponsor":"BeiGene","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • ER positive • BRCA1 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • ER positive • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 06/22/2018","start_date":" 06/22/2018","primary_txt":" Primary completion: 10/09/2020","primary_completion_date":" 10/09/2020","study_txt":" Completion: 04/14/2021","study_completion_date":" 04/14/2021","last_update_posted":"2022-09-07"},{"id":"b043b5ea-7b2a-4f87-aa2f-31a902029342","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327621","created_at":"2022-04-14T12:54:01.039Z","updated_at":"2024-07-02T16:36:12.745Z","phase":"Phase 2","brief_title":"Pamiparib in mCRPC With HRD or BRCA1/2 Mutation","source_id_and_acronym":"NCT05327621","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRCA1 • BRCA2 • AR","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 03/20/2025","primary_completion_date":" 03/20/2025","study_txt":" Completion: 03/20/2025","study_completion_date":" 03/20/2025","last_update_posted":"2022-04-14"},{"id":"3549e363-5331-4a84-93ac-99174729979c","acronym":"BGB-A317/BGB-290_Study_001","url":"https://clinicaltrials.gov/study/NCT02660034","created_at":"2021-01-17T17:13:22.882Z","updated_at":"2024-07-02T16:36:19.829Z","phase":"Phase 1","brief_title":"The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT02660034 - BGB-A317/BGB-290_Study_001","lead_sponsor":"BeiGene","biomarkers":" HER-2 • BRCA1 • BRCA2 • MSI • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR • HER-2 negative • HRD • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • MSI • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR • HER-2 negative • HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 229","initiation":"Initiation: 02/02/2016","start_date":" 02/02/2016","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 09/09/2020","study_completion_date":" 09/09/2020","last_update_posted":"2021-12-06"},{"id":"24564cf4-dd6c-4128-b446-ac0dcc6000d1","acronym":"PRECISE","url":"https://clinicaltrials.gov/study/NCT03933761","created_at":"2021-01-18T19:22:29.887Z","updated_at":"2024-07-02T16:36:26.727Z","phase":"Phase 2","brief_title":"Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy","source_id_and_acronym":"NCT03933761 - PRECISE","lead_sponsor":"Australia New Zealand Gynaecological Oncology Group","biomarkers":" BRCA1 • BRCA2 • ABCB1 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • ABCB1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/29/2019","start_date":" 07/29/2019","primary_txt":" Primary completion: 08/02/2021","primary_completion_date":" 08/02/2021","study_txt":" Completion: 08/02/2021","study_completion_date":" 08/02/2021","last_update_posted":"2021-08-10"},{"id":"148387d0-8f84-477d-85ca-cd9f19357c86","acronym":"BGB-290-AU-002","url":"https://clinicaltrials.gov/study/NCT02361723","created_at":"2021-01-18T11:14:33.883Z","updated_at":"2024-07-02T16:36:45.642Z","phase":"Phase 1a/1b","brief_title":"Phase 1a/1b BGB-290 for Advanced Solid Tumors.","source_id_and_acronym":"NCT02361723 - BGB-290-AU-002","lead_sponsor":"BeiGene","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Partruvix (pamiparib)"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 07/03/2014","start_date":" 07/03/2014","primary_txt":" Primary completion: 09/03/2019","primary_completion_date":" 09/03/2019","study_txt":" Completion: 09/03/2019","study_completion_date":" 09/03/2019","last_update_posted":"2020-04-24"}]